Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

• Published in: Brain Research Reviews Vol. 48; no. 2; pp. 379 - 387
• Main Authors: Mandel, Silvia, Weinreb, Orly, Amit, Tamar, Youdim, Moussa B.H.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Amsterdam Elsevier B.V 01.04.2005; Elsevier
• Subjects: Amyloid beta-Peptides - metabolism; Animals; Anticonvulsants. Antiepileptics. Antiparkinson agents; Apoptosis - drug effects; Bcl-2; Biological and medical sciences; Brain Chemistry - drug effects; Cell death; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Ferritins - metabolism; Humans; Indans - therapeutic use; Ladostigil; MAPK; Medical sciences; Mitochondria - drug effects; Models, Neurological; Monoamine Oxidase Inhibitors - chemistry; Monoamine Oxidase Inhibitors - therapeutic use; Neurology; Neuropharmacology; Neuroprotection; Neuroprotective Agents - therapeutic use; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson's disease; Pharmacology. Drug treatments; PKC; Propargylamine; Protein Kinase C - metabolism; Rasagiline; Signal Transduction - drug effects; Bcl-2; Disorders of the nervous system; Neuroprotection; Parkinson's disease; Propargylamine; Ladostigil; Cell death; Rasagiline; PKC; MAPK; Nervous system diseases; Enzyme; Mitogen-activated protein kinase; Parkinson disease; Review; Antiparkinson agent; Cerebral disorder; Central nervous system disease; Degenerative disease; Mechanism of action; Extrapyramidal syndrome

The mitochondria are directly involved in cell survival and death. Drugs that protect mitochondria viability and prevent apoptotic cascade mechanisms involved in mitochondrial permeability transition pore (MPTp) will be cytoprotective. Rasagiline ( N-propargyl-1R-aminoindan) is a novel, highly poten...